AE Wealth Management LLC bought a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 15,450 shares of the company’s stock, valued at approximately $48,000.
Several other hedge funds also recently made changes to their positions in the company. ARK Investment Management LLC raised its position in shares of Ginkgo Bioworks by 45.2% during the 3rd quarter. ARK Investment Management LLC now owns 126,818,856 shares of the company’s stock valued at $395,675,000 after acquiring an additional 39,460,799 shares in the last quarter. Baillie Gifford & Co. increased its stake in Ginkgo Bioworks by 22.4% during the second quarter. Baillie Gifford & Co. now owns 205,327,786 shares of the company’s stock valued at $488,680,000 after purchasing an additional 37,575,106 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Ginkgo Bioworks during the second quarter worth $52,022,000. State Street Corp lifted its position in shares of Ginkgo Bioworks by 210.3% in the 2nd quarter. State Street Corp now owns 12,411,855 shares of the company’s stock worth $29,540,000 after buying an additional 8,411,787 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its position in shares of Ginkgo Bioworks by 46.5% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 21,858,173 shares of the company’s stock worth $52,678,000 after buying an additional 6,937,185 shares during the last quarter. Institutional investors and hedge funds own 61.83% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have issued reports on DNA. Berenberg Bank started coverage on Ginkgo Bioworks in a research note on Monday, November 28th. They issued a “buy” rating and a $6.00 target price on the stock. Raymond James cut their price target on Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating on the stock in a report on Tuesday, November 22nd. Morgan Stanley started coverage on Ginkgo Bioworks in a report on Tuesday, October 4th. They issued an “equal weight” rating and a $5.00 price objective for the company. Finally, BTIG Research cut their target price on Ginkgo Bioworks to $4.00 in a research note on Thursday, November 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $5.92.
Ginkgo Bioworks Trading Down 8.7 %
Shares of Ginkgo Bioworks stock opened at $1.67 on Friday. The business has a fifty day simple moving average of $1.85 and a 200-day simple moving average of $2.54. The firm has a market cap of $3.24 billion, a price-to-earnings ratio of -0.73 and a beta of 0.68. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $1.45 and a fifty-two week high of $6.38. The company has a quick ratio of 11.67, a current ratio of 11.71 and a debt-to-equity ratio of 0.04.
Ginkgo Bioworks (NYSE:DNA – Get Rating) last posted its quarterly earnings data on Monday, November 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.15). Ginkgo Bioworks had a negative net margin of 668.49% and a negative return on equity of 85.90%. The business had revenue of $66.40 million for the quarter, compared to the consensus estimate of $54.28 million. On average, equities analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -1.41 EPS for the current fiscal year.
Ginkgo Bioworks Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.